Purpose P-glycoprotein (P-gp), encoded by MDR1 (or ABCB1), is important in anticancer drug delivery and resistance. We evaluated alterations in P-gp-mediated transport of anticancer agents due to the MDR1 G1199A polymorphism. Methods Using stable recombinant epithelial cells expressing wild-type (MDR1 wt ) or G1199A (MDR1 1199A ), anticancer drug sensitivity and transepithelial permeability were evaluated. Results The recombinant cells MDR1 wt and MDR1 1199A displayed comparable doxorubicin resistance. However, MDR1 1199A cells displayed greater resistance to vinblastine, vincristine, paclitaxel, and VP-16 (11-, 2.9-, 1.9-, and 2.9-fold, respectively). Alterations in transepithelial permeability paralleled these changes. EZux of doxorubicin was similar between MDR1 wt -and MDR1 1199A
Introduction
The human multidrug resistance gene (MDR1 or ABCB1) encodes a 170-kDa integral membrane protein, P-glycoprotein (P-gp), which mediates ATP-dependent substrate eZux. P-gp is a member of the ATP-binding cassette (ABC) superfamily of transporters that resides in the plasma membrane and functions as an eZux transporter for a wide variety of natural compounds and lipophilic xenobiotics [1] . Overexpression of P-gp in cancer cells causes a decrease in drug accumulation, thereby leading to the development of cellular resistance to anticancer agents. P-gp also plays a role in the pharmacokinetics and disposition of anticancer drugs via its high degree of expression in intestinal mucosa, liver canalicular membrane, kidney proximal tubules, blood-brain-barrier (BBB), and placenta [1] .
The sequence of MDR1 gene is highly variable with more than 60 single nucleotide polymorphisms (SNPs) identiWed in the coding region, and displays substantial linkage disequilibrium. Genetic variation in MDR1 has been shown to inXuence P-gp expression and function both in vitro and in vivo; however, results have been inconclusive and controversial [2] . Therefore, a systematic study designed to address the functional signiWcance of MDR1 genetic polymorphisms at the cellular and molecular levels is needed to deWne the impact on clinical pharmacokinetics. To accomplish this, we have developed a recombinant expression system in LLC-PK1 epithelial cells capable of expressing MDR1 variants in a reproducible manner [3] .
The model for this recombinant cell expression system was expression of the MDR1 G1199A SNP, which results in a serine to asparagine transition at amino acid 400 (Ser400Asn) in a cytoplasmic domain of P-gp (allelic frequency »5.5% in Caucasians) [3, 4] . Unlike other well recognized MDR1 polymorphisms (e.g. C1236T, G2677T, and C3435T), G1199A is not in linkage disequilibrium with other SNPs. In our expression, we conWrmed that similar levels of mRNA and protein are expressed in polarized LLC-PK1 cells expressing either wild-type MDR1 (MDR1 wt ) or the G1199A genetic polymorphism (MDR1 1199A ) [3] . We also demonstrated that MDR1 G1199A altered Pgp-mediated transport of a prototypic substrate, rhodamine-123, as well as HIV protease inhibitors [3, 5] . As a part of our initial study to validate these recombinant MDR1 cells, we reported that MDR1 G1199A altered cellular resistance to some anticancer agents in LLC-PK1 cells [3] . Our lab has also shown that MDR1 G1199A alters chemoresistance in recombinant HEK cells [6] ; and a recent study has shown MDR1 G1199A may be predictive of progression-free survival in patients receiving paclitaxel chemotherapy [7] . Therefore, it appears that MDR1 G1199A may be an important SNP in determining the clinical eYcacy of anticancer agents.
In this report, we further evaluated the inXuence of MDR1 G1199A on P-gp-mediated cellular resistance using an expanded panel of anticancer drugs, and compare the results to previous cytotoxic results. We also evaluated transepithelial permeability of anticancer agents in our recombinant system. Transepithelial permeability studies provide a tool to estimate the movement of a drug across a physiologic epithelial or endothelial membrane in the body; and therefore, predict distribution of drugs into target tissues in the body. Altered transepithelial permeability of anticancer agents due to MDR1 polymorphisms may be particularly important at the BBB where P-gp presents a major hurdle to anticancer drug delivery into the central nervous system (CNS) for the treatment of brain tumors. Cytotoxic drug sensitivity assay Sensitivity to cytotoxic anticancer agents was evaluated in LLC-PK1 control and MDR1 recombinant cells as described previously [3] . Varying concentrations of doxorubicin, vinblastine, paclitaxel, VP-16 (Bedford Laboratories, Bedford, OH), and vincristine (Faulding, Paramus, NJ) were added to the cells in quadruplicate. Cells were incubated with the cytotoxic drugs for 3 days at 37°C. On day 2 of the incubation, 1 Ci of 3 H-thymidine (speciWc activity: 81.1 Ci/mM) was added to each well and incubated overnight. Cell death was estimated by the amount of 3 H-thymidine incorporation into DNA of treated cells compared to untreated. Cytotoxicity was measured as the eVective drug concentration necessary for 50% cell death (EC 50 ) for each drug; EC 50 values were estimated using a sigmoid E max model on WinNonlin ® software (Pharsight, Mountain View, CA).
Materials and methods

Cell
Transepithelial permeability assay LLC-PK1 control and recombinant MDR1 cells were plated at a density of 2 £ 10 6 cells/24 mm well on permeable supports (Transwell™; 3.0 m membrane pore size; Corning) and grown for 4 days at 37°C in 5% CO 2 ; media was refreshed after 2 days. Fresh media was added to the cells 1 h before the initiation of the experiment, and transepithelial electrical resistance (TEER) values were measured with a Millicell®-ERS (Millipore, Billerica, MA). All transport assays were carried out at 37°C and corrections were made for the diVerence in volume in the apical and basolateral compartments. . Aliquots of 50 L were taken from apical and basal compartments up to 1 h for doxorubicin and up to 4 h for vinblastine and vincristine. Apparent permeability (P app ) was calculated in the apical-to-basolateral direction (P appA!B ) and in the basolateral-to-apical direction (P appB!A ) as described [5, 8] .
where A is the surface area of permeable support, C 0 is the initial concentration in the donor compartment, and dQ/dt is the rate of transfer of compound into the acceptor compartment. The ratio of P appB!A /P appA!B was estimated to evaluate P-gp-mediated directional eZux. Samples were run in quadruplicate.
Statistical analysis
Student's two-sided t test was used to evaluate diVerences between two sets of data. p < 0.05 were considered statistically signiWcant.
Results
Sensitivity to cytotoxic agents
Overexpression of P-gp in cancer cells often mediates the development of cellular resistance to doxorubicin, vinblastine, vincristine, paclitaxel, and VP-16 in tumor cells. Therefore, cellular sensitivity to these anticancer agents was evaluated based on a dose-response response curve and estimation of EC 50 values in LLC-PK1 control and MDR1 wt -and MDR1 1199A -expressing cells ( Table 1 ). The genotypic eVect of G1199A was not consistent across the drugs. As reported earlier, there was no diVerence in cellular sensitivity to doxorubicin was similar between MDR1 wtand MDR1 1199A -expressing cells, indicating G1199A does not inXuence P-gp-mediated resistance to doxorubicin [3] . However, a signiWcant eVect was observed in cellular sensitivities to vinblastine, vincristine, paclitaxel, and VP-16. Cells expressing MDR1 1199A displayed increased resistance to vinblastine (11-fold; p < 0.0005), vincristine (2.9-fold; p < 0.05), paclitaxel (1.9-fold; p < 0.0005), and VP-16 (> 2.9-fold; p < 0.0005) compared to cells expressing MDR1 wt . Therefore, the MDR1 G1199A polymorphism may be important in enhancing cellular resistance to these drugs. Collectively, these data suggest that the inXuence of G1199A on drug resistance, as well as the magnitude of the eVect, appears to be drug speciWc.
Transepithelial permeability P-gp is a directional transporter expressed on the apical membrane of epithelial cells and eZuxes substrates in a basolateral-to-apical direction. We evaluated diVerences in transepithelial permeability between MDR1 wt and MDR1 1199A cells by calculating the permeability ratio (P appB!A /P appA!B ) that represents the net Xux of a drug across an epithelial membrane. LLC-PK1 controls cells were expected to have low permeability ratios compared to cells expression MDR1. The potent P-gp inhibitor GF120918 was used to conWrm the role of P-gp-mediated transport. TEER values, which indicate the integrity of the monolayers and formation of tight junctions, averaged 358 § 47.8 cm 2 , which conWrmed a tight monolayer before the initiation of experiments.
For these experiments, we chose three representative drugs: doxorubicin, vincristine, and vinblastine. Doxorubicin provides equivalent sensitivity between wild-type and G1199A cells, while vincristine and vinblastine exhibit a higher degree of drug resistance in cells expressing G1199A. Transepithelial permeability ratios for doxorubicin, vinblastine, and vincristine are shown in Table 2 . For all three drugs, the estimates of the permeability ratios were derived from a linear range of transport across the epithelial cells, and therefore saturation of transport was not a factor. In the control cells, the permeability ratios were close to unity for doxorubicin, vinblastine, and vincristine, indicating no directional Xux, and the ratios were unaVected by 1199A in epithelial cells increased permeability ratios for doxorubicin, vinblastine, and vincristine compared to control cells, indicating that P-gp expression enhanced drug eZux in the recombinant cell system. We next compared the directional transepithelial permeability between MDR1 wt -and MDR1 1199A -expressing cells. We found no diVerence in the apparent permeability ratios for doxorubicin between MDR1 wt -and MDR1 1199A -expressing cells, indicating no genetic diVerence in the transport of doxorubicin. However, the apparent transepithelial permeability ratios were signiWcantly greater in cells expressing MDR1 1199A than MDR1 wt for both vinblastine (2.9-fold; p < 0.0001) and vincristine (2.0-fold; p < 0.005), indicating cells expressing the MDR1 G1199A polymorphism are more eYcient at mediating net directional Xux of vinblastine and vincristine across a polarized epithelial membrane. While we did observe a distinct genotypic eVect, the eVect appears to be drug speciWc, which is consistent with our observations in the cellular resistance experiments.
In the presence of the P-gp inhibitor, GF120918, permeability ratios were dramatically reduced in both MDR1 wt -and MDR1 1199A -expressing cells for vinblastine and vincristine. While doxorubicin permeability ratios were reduced, the results were not signiWcant. Genotypic diVerences observed in vinblastine and vincristine permeability ratios were also eliminated by GF120918 in MDR1 wt -and MDR1 1199A -expressing cells. Although the permeability ratios for vinblastine were not reduced to that of the control cells in the presence of GF120918, the values were similar between cells expressing MDR1 wt and MDR1 1199A . These data suggest that G1199A enhances the transepithelial permeability of vinblastine and vincristine, but not doxorubicin, by increasing P-gp-mediated transport.
Discussion
The development of multidrug resistance in cancer cells and tumors is a major obstacle in the chemotherapy. Many anticancer agents used clinically are substrates of P-gp, and expression of P-gp in cancer cells and tumors is a primary cause of drug resistance. Interindividual variation in P-gp activity, due to MDR1 polymorphisms, may inXuence distribution and delivery of anticancer agents to target cells and tissues. We have previously shown that recombinant cells expressing either MDR1 wt or MDR1 1199A provide a highly reliable and consistent method with which to evaluate functional changes in P-gp due to MDR1 pharmacogenetics [3, 5] . This system has now been used to study the phenotypic impacts of the G1199A polymorphism in transepithelial permeability and cellular sensitivities to anticancer agents. Our system provides the ability to predict how drugs will move across cellular barriers in the body, including the intestine, liver, kidney, and BBB. Since the majority of chemotherapeutic agents are administered intravenously, distribution across the BBB may be of considerable interest with respect to drug delivery, eYcacy, and toxicity.
Many anticancer agents have limited distribution into the CNS, partly due to poor penetration across BBB and eYcient removal by P-gp-mediated eZux transport [9] [10] [11] [12] [13] . However, some antineoplastic agents have had some success in treating brain tumors in vivo. Vincristine is currently included in many treatment programs for children with tumors arising within or outside the CNS [14, 15] . Doxorubicin and vincristine are also both often used in the treatment of brain tumors and neuroblastomas [16] [17] [18] . Alterations in P-gp activity, due to MDR1 polymorphisms, may inXuence anticancer agent distribution into the CNS as well as cellular sensitivity to cytotoxic drugs.
Utilizing our recombinant cell expression system, we evaluated the genotypic diVerences in cellular sensitivities to doxorubicin, vinblastine, vincristine, paclitaxel, and VP-16 in epithelial cells expressing either MDR1 wt or MDR1 1199A . While drug resistance to doxorubicin was similar between MDR1 wt -and MDR1 1199A -expressing cells, MDR1 1199A -expressing cells displayed signiWcantly enhanced resistance to vinblastine, vincristine, paclitaxel, and VP-16. This enhanced resistance in the MDR1 1199A -expressing cells would indicate that P-gp-mediated transport is enhanced in these cells. The resistance may be due to decreased intracellular accumulation, and therefore, reduced cytotoxicity. DiVerential sensitivity to anticancer agents may impact the eYcacy of chemotherapy, and these results may be useful We also assessed the role of MDR1 G1199A in P-gpdependent directional transepithelial permeability in our recombinant expression system and found that changes in transepithelial permeability correspond to the alterations observed in cellular sensitivities. Transepithelial permeability of doxorubicin was not aVected by expression of either MDR1 wt or MDR1 1199A indicating that the G1199A polymorphism does not impact doxorubicin disposition. Doxorubicin degradation in cardiomyocytes has been shown to be minimal even up to 4 h of incubation; therefore, we do not expect that extensive metabolism masked the eVect of diVerential transport by the G1199A SNP [19] . However, MDR1 1199A -expressing cells exhibited signiWcantly higher apparent transepithelial permeability ratios for both vinblastine and vincristine compared to cells expressing MDR1 wt . Therefore, our studies suggest that the eVect of the MDR1 G1199A polymorphism appears to be drug speciWc. LLC-PK1 cells express low levels of relevant drugmetabolizing enzymes; therefore, we do not expect that diVerential drug metabolism is playing a role in the drug speciWc pharmacogenomic eVect we observed [20] . Since the P-gp-mediated transport of vinblastine and vincristine is more eYcient in cells expressing MDR1 1199A , expression of G1199A may impact the permeability of anticancer agents across cell barriers in the body including the intestine, liver, kidney, and BBB. Since vinblastine and vincristine are administered intravenously, the eVect of G1199A polymorphism may be most pronounced in their delivery and distribution across the BBB and in their clearance from the body. Since the MDR1 G1199A polymorphism enhances transepithelial permeability of vinblastine and vincristine, we would expect that systemic clearance may be increased via enhanced biliary or renal secretion. Enhanced eZux at the BBB would contribute to further exclusion of distribution of vinblastine and vincristine into the brain. Therefore, our results indicate that distribution of vinblastine and vincristine into the CNS may be limited in cancer patients expressing G1199A, and that these patients may be more susceptible to the development of drug resistance.
The P-gp-mediated eZux of anticancer agents in MDR1 wt -and MDR1 1199A -expressing cells was almost completely inhibited in the presence of GF120918; that is, to the level of the control cells. These data indicate that the asymmetric eVect of G1199A expression on transepithelial permeability of anticancer agents fully reXects the alteration in P-gp function. While GF120918 may also inhibit the breast cancer resistance protein (BCRP), there was no eVect of GF120918 inhibition on the transepithelial permeability of anticancer agents in the control cells, indicating that BCRP does not play a role in our data interpretation.
In summary, we found that the MDR1 G1199A polymorphism alters cellular sensitivity and transepithelial permeability of anticancer agents in this recombinant cell system. However, the occurrence and magnitude of a G1199A eVect appears to be drug speciWc. MDR1 G1199A displayed no eVect on the disposition of doxorubicin, but signiWcantly enhanced drug resistance and transepithelial permeability of vinblastine and vincristine as well as enhanced drug resistance to paclitaxel and VP-16. The MDR1 G1199A polymorphism may impact cancer chemotherapeutic eYcacy by inXuencing delivery of anticancer agents to target cells and distribution into the CNS. Further phenotypegenotype association studies are needed to conWrm these predictions.
